iteratively adjusted α - FDA [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2015-12-08 10:35 (3354 d 21:29 ago) – Posting: # 15707
Views: 7,142

Dear Helmut, dear all,

one caveat: The results for the FDA highly depend on the assumption that empiric alpha is obtained if one simulates on the border of the 'implemented' acceptance ranges, i.e. 80-125% up to CVwR = 30% and for CVwR>30% at
100*exp((log(1.25)/0.25)*sqrt(log(1 + (CVwR/100)^2))) # CVwR in %
which has a discontinuity at CVwR = 30%.

This would be also my choice, but the paper

Davit et al.
"Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration"
AAPS Journal, Vol. 14, No. 4, December 2012

demands us to look at the widened implied limits from s0=0.25 on (CVwR ~ 25.4%), aka "FDA’s desired consumer risk model". Then the alpha inflation at the discontinuity CVwR = 30% vanishes. Its up to you to decide if this is real or some sort of hokus pokus.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,661 registered users;
28 visitors (0 registered, 28 guests [including 3 identified bots]).
Forum time: 08:04 CET (Europe/Vienna)

Everything is trivial, if you know the answer.    Thomas Jaki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5